Anti-Pr1/Hla-A2 Monoclonal Antibody Hu8F4
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Explore 39 assets in Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02530034CT.gov Hu8F4 in Treating Patients With Advanced Hematologic Malignancies | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Anti-Pr1/Hla-A2 Monoclonal Antibody Hu8F4 (this asset) | M.D. Anderson Cancer Center | P1 | CC · 43 |
| Fludarabine | Ohio State University Comprehensive Cancer Center | P2 | BBB |
| Cyclophosphamide | Ohio State University Comprehensive Cancer Center | P2 | BBB |
| Imatinib | The University of Hong Kong | P2 | BB |
| Tacrolimus | University of Michigan Rogel Cancer Center | P2 | BB |
| Nilotinib | The University of Hong Kong | P2 | BB |
| Busulfanum | Fred Hutchinson Cancer Center | P2 | BB |
| (+)-Vincristine | OHSU Knight Cancer Institute | P2 | BB |
| Romidepsin | M.D. Anderson Cancer Center | P2 | BB |
+42 more in the Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive cohort
Other indications for Anti-Pr1/Hla-A2 Monoclonal Antibody Hu8F4
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hematopoietic And Lymphoid Cell Neoplasm | — | P1 | CC · 43 |
| Myelodysplastic Syndrome | — | P1 | CC · 43 |
| Acute Myeloid Leukemia | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Anti-Pr1/Hla-A2 Monoclonal Antibody Hu8F4 in Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/anti-pr1hla-a2-monoclonal-antibody-hu8f4-blast-phase-chronic-myelogenous-leukemia-bcr-abl1-positive
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →